Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra
… genetics inform your health - but never limit it. Our Development department is currently looking for a highly … quantitative sciences and a passion for innovation in drugdevelopment. Location: Leiden, NL Key Responsibilities: …
… with internal and external partners, focused on the development of novel drug candidates for the treatment of chronic liver diseases. … of research efforts, driving innovation and efficiency in drugdevelopment. Proactively identify complex obstacles to …
… genetics inform your health - but never limit it. Our Development department is currently looking for an … skills to integrate biomarker science into all stages of drugdevelopment. Key Responsibilities: Strategic Leadership …
… Pharmacodynamic modelling expert to join our Translational Development Team. The Translational Development Team works in … Design, conduct and interpret these models to support drug screening and target validation, and to generate … and literature. Broad interest in different areas of drugdevelopment areas, such as molecular/cellular processes, …